2014-05-01T11:18:30-05:00 2013-06-30 ERNST & YOUNG US LLP 4370 LA JOLLA VILLAGE DRIVE 500 SAN DIEGO CA 92122 990 2012-07-01 952160097 THE SALK INSTITUTE FOR BIOLOGICAL STUDIES % KIM E WITMER SALK 8584534100 10010 N TORREY PINES ROAD Suite La Jolla CA 920371002 KIM E WITMER 2014-04-28 8585357200 2012 2015-11-30 17:44:51Z WILLIAM BRODY 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 177804987 false X WWW.SALK.EDU X 1960 CA BASIC RESEARCH IN THE FOLLOWING: MOLECULAR BIOLOGY & GENETICS, NEUROSCIENCE, AND PLANT BIOLOGY. 32 27 1084 151 3068 -7353 141948095 131344685 0 0 4142804 6538405 3114622 1670457 149205521 139553547 0 0 0 0 67662745 65503161 0 0 4743181 52389275 52056265 120052020 117559426 29153501 21994121 357920584 414387336 101386107 103916409 256534477 310470927 INVOLVED IN RESEARCH ACTIVITIES, THE OBJECTIVES OF WHICH ARE THE ADVANCEMENT AND DISSEMINATION OF KNOWLEDGE RELEVANT TO THE HEALTH AND WELLBEING OF MAN. THE OBJECTIVES ARE MET PRIMARILY THROUGH RESEARCH AND ADVANCED INSTRUCTION IN (A) BIOLOGY, (B) THE CAUSE, PREVENTION AND CURE OF DISEASES, AND (C) THE FACTORS AND CIRCUMSTANCES CONDUCIVE TO THE FULFILLMENT OF MAN'S BIOLOGICAL POTENTIAL. false false 101018096 LIST OF ACCOMPLISHMENTS 1. Salk scientists discover molecular link between circadian clock disturbances and inflammatory diseases A team of Salk scientists has found that the absence of a key circadian clock component called cryptochrome leads to the activation of a signaling system in the body that elevates levels of inflammatory molecules. The discovery may help those workers whose sleep-wake cycles are disrupted by night shifts, as this group has been shown to be more susceptible to chronic inflammatory conditions such as diabetes, obesity and cancer. In their report, published in Proceedings of the National Academy of Sciences, the Salk researchers demonstrated how a lack of cytochrome activated the NF-kB pathway, a molecular signaling conduit that controls many genes involved in inflammation. With this knowledge, the Salk team can now work to find a way to suppress NF-kB activation in the short term in order to treat inflammatory diseases. [8/1/12] 2. Planting the seeds of defense Although it has long been thought that methylation, a crucial part of normal organism development, was a static modification of DNA that could not be altered by environmental conditions, Salk researchers have proven otherwise. In exploring the immune system of Arabidopsis thaliana, a flowering plant in the mustard family, the scientists demonstrated that the DNA of organisms exposed to stress does undergo changes in DNA methylation patterns, ultimately altering how genes are regulated. In their study, published in the Proceedings of the National Academy of Sciences, they detailed how exposure to a pathogenic bacterium caused widespread changes in the plant's epigenetic code. These epigenetic changes were linked to the activity of genes responsible for coordinating a plant's response to stress, suggesting that the epigenome may help organisms develop resistance to pathogens and other environmental stressors. These findings have broad implications for agriculture, as thirty to forty percent of annual crops are lost to pathogens each year, at a cost of some $500 billion. [8/7/12] 3. What can the water monster teach us about tissue regeneration in humans? In order to understand how regeneration works at a molecular level, Salk scientists conducted two studies on the axolotl, a Mexican salamander whose name means "water monster." This unusual creature possesses the ability to regenerate many elements of its body, including its eyes, spinal cord and even parts of its brain. A key finding of this investigation was the identification of two proteins in the axolotl that help quiet "jumping genes," preventing them from moving around in the genomes of cells in tissue destined to regenerate. It is not yet known if humans even have all of the genes necessary for regeneration, but delving into how this process works may eventually lead to treatments for human conditions, such as wound healing. This novel research was published in both Development, Growth & Differentiation and Developmental Biology. [9/25/12] 4. Cold viruses point the way to new cancer therapies In a collaborative study, Salk researchers learned how adenovirus, a type of cold virus, has developed the tools to hijack a cell's molecular machinery. Using advanced imaging technologies, the team discovered that the virus produces small proteins that form a 3D web inside cells that traps and overpowers cellular sentries involved in growth and cancer suppression. These significant new findings, published in Cell, may help scientists develop small molecules-the basis for the vast majority of current drugs-capable of destroying tumors by binding and disrupting complex cellular components that allow cancer cells to grow and spread. Understanding how viruses overcome healthy cells may also help scientists engineer tumor-busting viruses, offering a unique and potentially self-perpetuating cancer therapy. [10/16/12] 5. Salk scientists pinpoint key player in Parkinson's disease neuron loss By reprogramming skin cells from Parkinson's disease patients with a known genetic mutation, Salk scientists have identified damage to neural stem cells as a powerful player in the disease. In their study, which was reported in Nature, the Salk team was able to use targeted gene-editing technologies to correct the mutation in patients' nuclear stem cells. This genetic correction repaired the disorganization of the nuclear envelope and improved overall survival and functioning of the neural stem cells. The researchers were also able to inhibit damage to the nucleus chemically, producing the same results seen with genetic correction. These important new findings offer clinicians an additional tool for diagnosing Parkinson's and open a door for drug treatment for those Parkinson's patients who have this genetic mutation. [10/19/12] 6. Aggressive brain tumors can originate from a range of nervous system cells In a groundbreaking study of glioblastoma multiforme (GBM), the most aggressive type of primary brain tumors, Salk researchers reported that the tumors can originate from several types of differentiated cells in the nervous system, including cortical neurons. Prior to this discovery, it was believed that GBM began only in the glial cells that make up supportive tissue in the brain or in neural stem cells. The findings help explain the recurrence of gliomas following treatment and suggest potential new targets to battle these deadly cancers. The Salk team published their paper in Science. [10/22/12] 7. Salk study finds diabetes raises levels of proteins linked to Alzheimer's features In a study published in Aging Cell, Salk researchers demonstrated for the first time that diabetes elicits a wide range of pathological changes in the brain and causes accelerated brain aging. Two hallmarks of Alzheimer's-accumulations of amyloid beta and tau protein-were identified in the brains of diabetic mice, especially in the cells surrounding blood vessels. This discovery by the Salk team suggests that the neurovascular system may be a good candidate for new therapeutic targets to treat Alzheimer's in the early stages of the disease. [10/26/12] 8. More than 3,000 epigenetic switches control daily liver cycles Salk scientists have identified the specific genetic switches in mice that synchronize liver activity with the circadian cycle, and have reported their findings in Cell Metabolism. While the team knew that genes in the liver turned on and off at different times of the day, and that the genes were involved in metabolizing substances such as fat and cholesterol, they had not previously located the switches for this activity. Their discovery lends further insight into the mechanisms behind such health-threatening conditions as high blood sugar and high cholesterol, and could pave the way for future therapies to treat these ever more prevalent conditions. [12/10/12] 9. Chromosome "anchors" organize DNA during cell division Salk scientists have discovered a new characteristic of human cell division that may help explain how DNA is organized in the nucleus as cells reproduce. Using advanced time-lapse, live-cell confocal microscopy to track the movement of telomeres, molecular caps that protect the ends of the chromosomes, in real time throughout the cell cycle, the researchers found that the telomeres move to the outer edge of the cell's nucleus after they have been duplicated. While the implications of this spatial reorganization are not yet clear, the findings may shed light on how our genes are regulated and how gene expression programs are altered during cell division, an important step in understanding aging and disease that stem from genetic mutations, such as cancer. [12/20/12] 10. Diabetes drug could hold promise for lung cancer patients In a study reported in Cancer Cell, Salk scientists have found that phenformin, a derivative of the widely used diabetes drug metformin, decreased the size of lung tumors in mice and increased the animals' survival. The discovery may give hope to the nearly 30 percent of patients with non-small cell lung cancer whose tumors lack LKB1. Cells that lack LKB1 are unable to sense metabolic stress and, as a result, run out of cellular energy and undergo apoptosis, or programmed cell death. With further clinical investigation and accompanying human studies, phenformin as an anti-cancer agent could be a reality in the next several years. [1/29/13] 11. How the brain keeps track of similar but distinct memories A team of Salk scientists has discovered how the dentate gyrus, a subregion of the hippocampus, helps keep memories of similar events and environments separate. Using laboratory techniques for tracking the activity of neurons at multiple time points, the scientists compared the functioning of the mouse dentate gyrus and another region of the hippocampus, known as CA1. They learned that in CA1, the same neurons were active during the learning and retrieval of memories. In the dentate gyrus, however, 101018096 true true false true false false false false false true true true false false true false true false false false true false false false true false false false false true true false false false false false false false false false false true false false false false true true false false false true 132 0 true 1084 true true true false false false false true true false false false false X 32 27 false false false false true true true true true false false true true true true true true true true false AL AK AZ AR CA CT GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NY NC OH OK OR PA RI SC TN UT VA WA WV WI X KIM E WITMER 8584534100 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 X William R Brody MD PhD 50.0 0.0 X X 827150 0 144393 Irwin M Jacobs SM ScD 3.0 0.0 X X 0 0 0 Darlene M Shiley 2.0 0.0 X X 0 0 0 Theodore Waitt 2.0 0.0 X X 0 0 0 Thomas D Albright PhD 50.0 0.0 X 246616 0 47170 Charles H Brandes 2.0 0.0 X 0 0 0 Linda L Chester 0.5 0.0 X 0 0 0 Frederick J Dotzler 0.5 0.0 X 0 0 0 Jennifer L Howse PhD 0.5 0.0 X 0 0 0 Dean Kamen 0.5 0.0 X 0 0 0 Christoper R Kintner PHD 50.0 0.0 X 206299 0 31498 Benjamin H Lewis 0.5 0.0 X 0 0 0 Corinne Mentzelopoulos 0.5 0.0 X 0 0 0 Howard H Newman PhD 2.0 0.0 X 0 0 0 Ralph S O'Connor 0.5 0.0 X 0 0 0 Gerald S Parsky 0.5 0.0 X 0 0 0 Frederik Paulsen PhD 0.5 0.0 X 0 0 0 Caryl Philips 0.5 0.0 X 0 0 0 Conrad T Prebys 0.5 0.0 X 0 0 0 Ernest S Rady 0.5 0.0 X 0 0 0 Faye Hunter 0.5 0.0 X 0 0 0 Mary Jane Salk 0.5 0.0 X 0 0 0 Benjamin S Schapiro 0.5 0.0 X 0 0 0 Carla J Shatz PhD 0.5 0.0 X 0 0 0 Jerre L Stead 2.0 0.0 X 0 0 0 Geoffrey M Wahl PhD 50.0 0.0 X 256293 0 45615 Harvey P White 0.5 0.0 X 0 0 0 Marna C Whittington PhD 0.5 0.0 X 0 0 0 M Faye Wilson 0.5 0.0 X 0 0 0 Daniel C Lewis 0.5 0.0 X 0 0 0 Sanjay K Jha PhD 0.5 0.0 X 0 0 0 John A T Young PhD 50.0 0.0 X 252259 0 33288 Marsha A Chandler PhD 50.0 0.0 X 477955 0 33958 Julia A Miller JD 50.0 0.0 X 249581 0 47941 Kim E Witmer 50.0 0.0 X 363082 0 47941 Fred H Gage PhD 50.0 0.0 X 321388 0 44393 Rebecca R Newman 50.0 0.0 X 344640 0 35675 Inder Verma PhD 50.0 0.0 X 375879 0 44393 Anthony Hunter Ph D 50.0 0.0 X 305803 0 47941 Robert MacWright 50.0 0.0 X 313331 0 11795 4540276 0 616001 79 false true false RUDOLPH SLETTEN INC 10955 VISTA SORRENTO PKWY SAN DIEGO CA 92130 General Contractor 896702 UC REGENTS SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 TRNG PROGRAM/SUBCONT 1412102 SECURITAS SECURITY SERVICE FILE 57220 LOS ANGELES CA 90074 SECURITY 460137 COOLEY LLP 101 CALIFORNINA STREET 5TH FLOOR SAN FRANCISCO CA 94111 LEGAL 301948 MOSS ADAMS LLP 9665 GRANITE RIDGE DR SUITE 600 SAN DIEGO CA 92123 AUDIT 169000 7 760325 62005784 68578576 5294622 131344685 0 2736864 2736864 0 1594642 1594642 0 0 0 41554462 259862 37918332 94451 3636130 165411 3801541 3801541 140950 760325 238657 -97707 -97707 0 0 ENERGY REBATE 900099 167503 167503 OIL ROYALTIES 900099 2951 2951 UBI(K-1 FLOW THROUGH INCOME) 900099 2556 2556 512 512 173522 139553547 3068 8205794 0 0 0 0 3311040 1119039 1997692 194309 274552 274552 47178653 40750524 4081887 2346242 4313539 3547128 552374 214037 7045857 5793980 902263 349614 3379520 2779062 432767 167691 295230 68750 199359 27121 1377663 1276642 101021 157482 157482 0 0 203400 203400 6142035 5438458 499388 204189 39116 39116 12566116 11983615 158365 424136 2475424 2031201 357937 86286 0 6640529 5241619 1235042 163868 884265 794026 36925 53314 0 1110599 812286 75881 222432 0 0 12063710 11294727 533949 235034 134418 134418 SCIENTIFIC SUBCONTRACTS 7308050 7308050 REPAIRS & PARTS 479387 439736 35102 4549 UBI TAXES 50 50 OTHER EXPENSES 178791 64701 102847 11243 117559426 101018096 11798149 4743181 12698201 16516340 0 0 28220160 29141141 922755 986272 148500 0 0 1608475 2082734 86205 33600 678625 809375 217136661 132239738 87805456 84896923 118874737 155257977 100033993 117441415 0 0 0 0 6843477 7221559 357920584 414387336 17196676 16458795 0 0 21168387 27075747 56129568 54547056 0 0 0 0 0 0 0 0 6891476 5834811 101386107 103916409 X 78170627 91663539 63947145 79698709 114416705 139108679 256534477 310470927 357920584 414387336 X 21994121 30754843 1187486 X false true X true true true X 87583830 114311374 120830531 141948096 131344685 596018516 0 0 87583830 114311374 120830531 141948096 131344685 596018516 19894632 576123884 2714020 3494564 3483205 4407819 4331506 18431114 44457 3701 48158 3678 222177 18981 407374 170454 822664 615320452 0.93630 0.94819 X Description: GLASS ART TOUR 2008: 0 2009: 210,825 2010: 0 2011: 0 2012: 0 Description: OIL ROYALTIES 2008: 3,678 2009: 7,692 2010: 16,701 2011: 6,794 2012: 2,951 Description: NOTE RECEIVABLE INTEREST 2008: 0 2009: 3,660 2010: 2,280 2011: 0 2012: 462 Description: ENERGY REBATE 2008: 0 2009: 0 2010: 0 2011: 400,580 2012: 167,503 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 1680 1680 false OTHER ACTIVITIES PART II-B, LINE 1i PAID MEMBERSHIP DUES TO RESEARCH AND BIOMEDICAL ORGANIZATIONS, A PORTION OF WHICH ARE CONSIDERED LOBBYING. ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES $ 720 NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH $ 960 126725558 24531449 20361663 3981493 167637177 113493623 18776974 -1376528 4168510 126725559 89420545 12288420 15274598 3489940 113493623 71360759 11356891 8833640 2130745 89420545 83049682 2721386 -12462264 1948045 71360759 0.00950 0.99050 false false 1153930 1153930 68485570 39431619 29053951 75612188 41205886 34406302 71649870 51602233 20047637 235103 235103 84896923 ALTERNATIVE INVESTMENTS 117438301 F STOCKS NOT-PUBLICLY TRADED <5% 3114 C 117441415 2052 DEFERRED RETIREMENT OBLIGATION 5832759 5834811 141392346 30754843 -29154702 1600141 139792205 -238658 -238658 139553547 117798080 238658 238658 117559422 4 4 117559426 RECONCILIATION OF REVENUE PER AUDITED FS WITH REVENUE PER RETURN Part XI, Lines 2d Investment return in excess of amount designated for current operations under spending policy, UBI (K-1 flow through income), and rounding. Reconciliation of Revenue per Audited FS with Revenue per Return Part XI, Line 4b Fundraising events expenses. ENDOWMENT FUNDS USES PART V, LINE 4 ENDOWMENT INCOME INTENDED TO BE USED FOR AND TO SUPPORT RESEARCH, OPERATIONS, AND LECTURESHIP EXPENSES. Reconciliation of Expenses per Audited FS with Expenses per Return Part XII, Line 2d Fundraising events expenses. Reconciliation of Expenses per Audited Financial Stmts w Expenses per Rtn Part XII, Line 4b Rounding. Europe (Including Iceland and Greenland) Program Services Attended conference 137288 East Asia and the Pacific Program Services Attended conference 36915 Middle East and North Africa Program Services Attended conference 4996 South America Program Services Attended conference 4614 North America Program Services Attended conference 4002 Central America and the Caribbean Program Services Attended conference 2187 Europe (Including Iceland and Greenland) Program Services Scientific subcontract 103531 North America Program Services Scientific subcontract 38371 East Asia and the Pacific Program Services Scientific subcontract 29982 Central America and the Caribbean Investments 84256134 84618020 84618020 true false false true true false NO. OF EMPLOYEES IN THE REGION PART I, LINE 3, COLUMN (C) SCIENTISTS TRAVEL TO FOREIGN COUNTRIES TO ATTEND CONFERENCES. WE DO NOT DEEM THESE ACTIVITIES TO CONSTITUTE WORKING IN THE REGION. ACCOUNTING METHOD PART I, LINE 3, COLUMN (F) ACCRUAL METHOD CONCERT 901275 760325 140950 81657 157000 0 0 0 0 0 0 0 0 0 0 901275 760325 140950 0 0 0 81657 157000 0 238657 -97707 X X true true X X X X X X true true false false false false false true false William R Brody MD PhD 666482 0 0 0 160668 0 132500 0 11893 0 971543 0 0 0 Thomas D Albright PhD 239330 0 0 0 7286 0 32029 0 15141 0 293786 0 0 0 Christoper R Kintner PHD 191232 0 0 0 15067 0 26000 0 5498 0 237797 0 0 0 Geoffrey M Wahl PhD 252594 0 0 0 3699 0 32500 0 13115 0 301908 0 0 0 Marsha A Chandler PhD 425916 0 0 0 52039 0 32500 0 1458 0 511913 0 0 0 Julia A Miller JD 248706 0 0 0 875 0 32500 0 15441 0 297522 0 0 0 Kim E Witmer 326520 0 0 0 36562 0 32500 0 15441 0 411023 0 0 0 Fred H Gage PhD 316842 0 0 0 4546 0 32500 0 11893 0 365781 0 0 0 Rebecca R Newman 306316 0 0 0 38324 0 32500 0 3175 0 380315 0 0 0 Inder Verma PhD 366842 0 0 0 9037 0 32500 0 11893 0 420272 0 0 0 Anthony Hunter Ph D 282332 0 0 0 23471 0 32500 0 15441 0 353744 0 0 0 Robert MacWright 270165 0 0 0 43166 0 0 0 11795 0 325126 0 0 0 John A T Young PhD 241144 0 0 0 11115 0 31408 0 1880 0 285547 0 0 0 QUESTIONS REGARDING COMPENSATION PART I, LINE 1A FIRST-CLASS OR CHARTER TRAVEL: DENNIS O'LEARY, PROFESSOR - $471 AND JOHN YOUNG, PROFESSOR - $1,353; NOT TAXABLE - ACCOUNTABLE PLAN. QUESTIONS REGARDING HOUSING ALLOWANCE OR RESIDENCE PART I, LINE 1A A HOUSING ALLOWANCE IS PROVIDED AND REPORTED AS TAXABLE COMPENSATION. SEVERANCE PART I, LINE 4A SEVERANCE WAS RECEIVED BY ROBERT MACWRIGHT, SR. DIR., OFC OF TECH DEV, IN THE AMOUNT OF $23,667. SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B DEFERRED COMPENSATION PLAN (SECTION 457(F)) WAS ESTABLISHED FOR THE PRESIDENT. THE INSTITUTE'S CONTRIBUTION TO THE PLAN AND THE EARNINGS FROM THE CONTRIBUTION WILL BECOME 100% VESTED UPON THE PRESIDENT'S COMPLETION OF 5 YEARS OF SERVICE. NO PAYOUTS FROM THE PLAN WERE MADE DURING THE YEAR. NON-FIXED PAYMENTS PART I, LINE 7 NON-FIXED PAYMENTS INCLUDE BOARD OF TRUSTEE AWARDS WHICH ARE REPORTED UNDER OTHER REPORTABLE COMPENSATION. THE BOARD OF TRUSTEE AWARDS ARE NON-BASE RECOGNITION AWARDS FOR CERTAIN LISTED INDIVIDUALS, AS APPROVED BY THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES. NON-BASE RECOGNITION AWARDS ARE INCLUDED IN THE TOTAL COMPENSATION PACKAGES SUBJECT TO THE REVIEW PROCESS DESCRIBED IN SCHEDULE O, FORM 990, PART VI, SECTION B, LINE 15B. A CA STATEWIDE COMM DEV AUTHORITY 680164610 130911S92 2005-08-11 25712839 REFUND 03/30/94 ISSUE false false false B COUNTY OF SAN DIEGO 956000934 797391R50 2010-05-27 37207949 REFUND 04/13/00 ISSUE;RENOVATE/EQU false false false A 7380000 0 25712839 0 0 0 686939 0 0 0 0 0 true false true true B 790000 0 37207949 0 0 0 523682 0 0 23537429 0 0 2012 true false true true A 0.00000 0.00000 0.00000 B false true false false 0.00000 0.00000 0.00000 true false false true A false false true false false false 0 false 0 false true B false false true false false false 0 false 0 false true A true B true X 19 4913922 MARKET VALUE X 2 380700 APPRAISED VALUE false true false GOVERNING BODY AND MANAGEMENT FORM 990, PART VI, SECTION A, LINES 1a, 6, 7a, 7b LINE 1A: THE EXECUTIVE COMMITTEE SHALL ADVISE AND AID THE OFFICERS OF THE CORPORATION IN ALL MATTERS CONCERNING ITS INTERESTS, INCLUDING WITHOUT LIMITATION ALL MATTERS RELATING TO COMPENSATION AND BENEFITS, AND SHALL POSSESS AND MAY EXERCISE, DURING THE INTERVALS BETWEEN THE MEETINGS OF THE BOARD OF TRUSTEES, ALL THE POWERS AND AUTHORITY OF THE BOARD OF TRUSTEES IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE CORPORATION, INCLUDING THE POWER TO AUTHORIZE THE CORPORATE SEAL TO BE AFFIXED TO ANY AND ALL DOCUMENTS WHICH MAY REQUIRE THE SAME TO BE AFFIXED THERETO, INSOFAR AS SUCH SEEMS TO THE EXECUTIVE COMMITTEE FOR THE BEST INTERESTS OF THE CORPORATION, IN ALL CASES IN WHICH SPECIFIC DIRECTIONS SHALL NOT HAVE BEEN GIVEN BY THE BOARD OF TRUSTEES, EXCEPT THAT THE EXECUTIVE COMMITTE SHALL HAVE NO POWER TO ADOPT, AMEND, OR REPEAL THE BY-LAWS. LINE 6: MEMBERSHIP OF THE CORPORATION CONSISTS OF THE PERSONS ELECTED TO THE BOARD OF TRUSTEES AND THREE MEMBERS FROM AMONG THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS CHOSEN AND ELECTED ANNUALLY BY THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS. LINE 7a: THE MEMBERS OF THE CORPORATION ELECT THE TRUSTEES. LINE 7b: THE MEMBERS OF THE CORPORATION MAY ALTER, AMEND, OR REPEAL THE BY-LAWS BY VOTE. POLICIES FORM 990, PART VI, SECTION B, LINES 11B, 12C AND 15A/B LINE 11B: THE FORM 990 IS PREPARED BY THE INSTITUTE, INTERNALLY REVIEWED BY THE SR. DIRECTOR OF FINANCE AND THE CHIEF FINANCIAL OFFICER AND EXTERNALLY REVIEWED BY THE TAX DEPARTMENT OF A PUBLIC ACCOUNTING FIRM. A COPY OF THE PREPARED FORM 990 IS PROVIDED TO ALL BOARD MEMBERS AND THE AUDIT COMMITTEE FOR REVIEW AND DISCUSSION PRIOR TO ELECTRONIC FILING. LINE 12C: ANNUALLY, THE CONFLICT OF INTEREST DISCLOSURE STATEMENT IS SENT OUT FOR COMPLETION BY THE MEMBERS OF THE BOARD OF TRUSTEES, SENIOR MEMBERS OF ADMINISTRATION AND RESEARCHERS. THE DESIGNATED OFFICIAL FOR EACH GROUP REVIEWS THE COMPLETED FORMS AND BRINGS ANY POTENTIAL CONFLICT OF INTEREST TO THE RESPECTIVE COMMITTEES FOR REVIEW. UPON DETERMINATION THAT A CONFLICT OF INTEREST EXISTS, THE FOLLOWING CONDITIONS OR RESTRICTIONS MAY BE IMPOSED: A. MONITORING OF ACTIVITIES GENERATING THE CONFLICT BY ANOTHER MEMBER; B. DISQUALIFICATION FROM PARTICIPATION IN THE ACTIVITIES GIVING RISE TO THE CONFLICT; C. MODIFICATION OF RESPONSIBILITIES TO AVOID CONFLICTS; D. PUBLIC DISCLOSURE OR DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS; E. MODIFICATION OF THE RESEARCH PLAN OR REMOVAL OF THE AFFECTED RESEARCHER FROM THE RESEARCH; F. SEVERANCE OF RELATIONSHIP THAT CREATES ACTUAL OR POTENTIAL CONFLICTS; G. TERMINATION OF EMPLOYMENT. LINE 15A/B:IN 2011, AN INDEPENDENT CONSULTANT WAS RETAINED BY THE SALK INSTITUTE TO ADVISE ON CALENDAR YEAR 2012 COMPENSATION ISSUES. THIS INDEPENDENT CONSULTANT, UTILIZING IDENTICAL METHODOLOGY, UPDATED THE 2010 MARKET ANALYSIS HE CONDUCTED ON THE COMPETITIVENESS OF THE BASE SALARY AND TOTAL COMPENSATION (INCLUDING BENEFITS) FOR THE PRESIDENT, EXECUTIVE VICE PRESIDENT, AND CHIEF FIANANCIAL OFFICER. TOTAL COMPENSATION WAS COMPARED TO LIKE ROLES AMONG ORGANIZATIONS PROVIDING SIMILAR SERVICES IN THE RESEARCH INDUSTRY, INCLUDING BOTH FOR-PROFIT AND NOT-FOR-PROFIT ORGANIZATIONS. THE CONSULTANT CONSIDERED THE SIZE AND SCOPE OF OPERATIONS OF THE INCUMBENTS AND THE GUIDELINES ARTICULATED IN THE SALK INSTIUTUTE EXECUTIVE COMPENSATION POLICY. THE CONSULTANT INCLUDED REQUESTED NON-BASE PERFORMANCE RECOGNITION AWARDS FOR BOTH THE COO AND CFO POSITIONS IN THE TOTAL COMPENSATION COMPARISON. THE CONSULTANT GAVE THE OPINION THAT THE TOTAL COMPENSATION, INCLUDING THE REQUESTED NON-BASE AWARDS, WAS WELL WITHIN THE REASONABLE RANGE OF COMPETITIVE PRACTICES. HUMAN RESOURCES COMPLETED A SIMILAR TOTAL COMPENSATION ANALYSIS FOR THE VP, DEVELOPMENT AND COMMUNICATIONS AND THE VP, ACADEMIC AND ADMINISTRATIVE SERVICES POSITIONS. THE COMPENSATION COMMITTEE WAS PROVIDED MARKET DATA OF LIKE ROLES AMONG ORGANIZATIONS PROVIDING SIMILAR SERVICES IN THE RESEARCH INDUSTRY AND NOT-FOR-PROFIT SECTORS. NON-BASE PERFORMANCE RECOGNITION AWARDS FOR THESE TWO POSITIONS WERE ALSO INCLUDED IN THE TOTAL COMPENSATION REVIEW. HUMAN RESOURCES GAVE THE OPINION THAT THE TOTAL COMPENSATION, INCLUDING THE REQUESTED NON-BASE AWARDS, WAS WELL WITHIN THE REASONABLE RANGE OF COMPETITIVE PRACTICES AND IN LINE WITH THE GUIDELINES ARTICULATED IN THE SALK INSTIUTUTE EXECUTIVE COMPENSATION POLICY. DOCUMENTATION ON COMPLETION OF ANNUAL GOALS AND ACHIEVEMENTS WAS PRESENTED TO THE COMPENSATION COMMITTEE SUPPORTING THE PERFORMANCE RECOGNITION AWARDS. THE CONSULTANT'S AND HUMAN RESOURCES' REPORTS WERE REVIEWED BY THE EXECUTIVE COMMITTEE WHICH SERVED AS THE COMPENSATION COMMITTEE, EXCLUDING PERSONS WITH A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENTS. THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION ACTIONS WERE INCLUDED IN THE MINUTES OF THE EXECUTIVE COMMITTEE MEETING. COPIES OF THE CONSULTANT'S AND HUMAN RESOURCES' REPORTS WERE ATTACHED TO THE MINUTES OF THE MEETING. DISCLOSURE FORM 990, PART VI, SECTION C, LINE 19 UPON REQUEST, THE OFFICE OF THE CHIEF FINANCIAL OFFICER MAKES AVAILABLE TO THE PUBLIC ITS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY. FINANCIAL STATEMENTS ARE AVAILABLE ON THE SALK WEB SITE. OTHER CHANGES IN NET ASSETS FORM 990, PART XI, LINE 9 POSTRETIREMENT BENEFIT CHANGES OTHER THAN NET PERIODIC BENEFIT COST - $1,186,849; UBI ((K-1 FLOW THROUGH INCOME) - $2,556; ROUNDING - ($1,919) COMPENSATION OF DIRECTORS PART VII, DIRECTORS COMPENSATION THE FOLLOWING INDIVIDUALS WERE COMPENSATED FOR THE FOLLOWING SERVICES AND NOT PAID AS TRUSTEES: GEOFFREY M. WAHL, PH.D. - PROFESSOR THOMAS D. ALBRIGHT, PH.D. - PROFESSOR CHRISTOPHER R. KINTNER, PH.D. - PROFESSOR; JOHN A.T. YOUNG, PH.D. - PROFESSOR. LA JOLLA BIOLOGICAL LABORATORIES 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 953655649 Research CA 501(C)(3) 11-I NA true SALK INSTITUTE COMMERCIAL SERVICES CORP 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 232159172 MGMT SERVICES PA SALK INSTITUTE C 51 51707 1.00000 true false false false false false false false false false false false false false true true false true false false